Medite Cancer Diagnostics, Inc.
MDIT
$0.00
$0.000.00%
| 09/30/2018 | 06/30/2018 | 03/31/2018 | 12/31/2017 | 09/30/2017 | |
|---|---|---|---|---|---|
| Revenue | 19.50% | -0.46% | -28.57% | -26.25% | -32.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.50% | -0.46% | -28.57% | -26.25% | -32.56% |
| Cost of Revenue | 17.76% | 24.75% | 17.91% | 18.60% | -14.34% |
| Gross Profit | 25.44% | -61.86% | -105.40% | -95.54% | -61.00% |
| SG&A Expenses | 19.89% | 29.10% | 53.67% | 46.67% | 24.54% |
| Depreciation & Amortization | 2.93% | 52.31% | 48.58% | 36.92% | 15.68% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.22% | 19.33% | 23.20% | 23.06% | 0.14% |
| Operating Income | 8.73% | -63.63% | -270.06% | -297.29% | -269.55% |
| Income Before Tax | -9.00% | -65.38% | -194.71% | -218.00% | -223.60% |
| Income Tax Expenses | -323.48% | -299.18% | -268.94% | -268.94% | -255.41% |
| Earnings from Continuing Operations | -2.07% | -58.10% | -190.79% | -214.89% | -203.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.07% | -58.10% | -190.79% | -214.89% | -203.02% |
| EBIT | 8.73% | -63.63% | -270.06% | -297.29% | -269.55% |
| EBITDA | 9.47% | -64.42% | -298.09% | -335.80% | -330.13% |
| EPS Basic | 30.71% | -15.49% | -113.95% | -144.57% | -147.15% |
| Normalized Basic EPS | 20.09% | -30.18% | -139.48% | -150.00% | -163.01% |
| EPS Diluted | 30.71% | -15.49% | -113.95% | -144.57% | -147.15% |
| Normalized Diluted EPS | 20.09% | -30.18% | -139.48% | -150.00% | -163.01% |
| Average Basic Shares Outstanding | 98.94% | 64.43% | 39.66% | 23.79% | 17.62% |
| Average Diluted Shares Outstanding | 98.94% | 64.43% | 39.66% | 23.79% | 17.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
